Bacterial keratitis due to Moraxella nonliquefaciens.
Queratitis bacteriana por Moraxella nonliquefaciens.
Aged
Amoxicillin-Potassium Clavulanate Combination
/ therapeutic use
Anti-Bacterial Agents
/ therapeutic use
Ceftazidime
/ therapeutic use
Ciprofloxacin
/ therapeutic use
Corneal Opacity
/ etiology
Corneal Ulcer
/ drug therapy
Drug Substitution
Eye Infections, Bacterial
/ drug therapy
Humans
Hyphema
/ etiology
Male
Moraxella
/ isolation & purification
Moraxellaceae Infections
/ drug therapy
Vancomycin
/ therapeutic use
Alteraciones oculares
Bacterial keratitis
Hifema
Hyphaema
Moraxella nonliquefaciens
Ocular alterations
Queratitis bacteriana
Journal
Archivos de la Sociedad Espanola de Oftalmologia
ISSN: 2173-5794
Titre abrégé: Arch Soc Esp Oftalmol (Engl Ed)
Pays: Spain
ID NLM: 101715860
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
10
12
2019
revised:
18
02
2020
accepted:
19
02
2020
pubmed:
4
4
2020
medline:
8
6
2021
entrez:
4
4
2020
Statut:
ppublish
Résumé
Moraxella keratitis can lead to important complications. Moraxella nonliquefaciens(M. nonliquefaciens) has the worst prognosis. Only three cases of corneal infections due to M. nonliquefaciens have been published. The case is presented of a 79-year-old man with bullous keratopathy, recently affected with severe infectious keratitis. Dense, deep, and central stromal infiltrates and hyphaema were detected. After the identification of M. nonliquefaciens in the culture, and given the progression of the condition, the initial empirical treatment was modified to topical ciprofloxacin and ceftazidime in accordance with the antibiogram, combining oral ciprofloxacin and amoxicillin-clavulanate. After 27 days, there was total resolution of the lesion, with central residual leucoma. Keratitis caused by M. nonliquefaciens is rare and must be suspected in elderly patients with local predisposing factors, such as corneal damage or previous eye surgery. Early antibiogram-guided treatment and close monitoring are important to avoid complications and poor compliance.
Identifiants
pubmed: 32241585
pii: S0365-6691(20)30077-0
doi: 10.1016/j.oftal.2020.02.012
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ciprofloxacin
5E8K9I0O4U
Vancomycin
6Q205EH1VU
Amoxicillin-Potassium Clavulanate Combination
74469-00-4
Ceftazidime
9M416Z9QNR
Types de publication
Case Reports
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
357-360Informations de copyright
Copyright © 2020. Publicado por Elsevier España, S.L.U.